Main Director of BPJS Health, Prof. Dr. Ali Ghufron Mukti, M.Sc, Ph.D., welcomed the discussion to find efficient solutions to the burden of dengue disease and emphasized the role of BPJS in providing health protection.
“In 2023, the funding issued by BPJS Health for handling dengue will reach IDR 1.3 trillion. This figure is up from IDR 626 billion in the previous year,” he said.
PAPDI representative, Prof. Dr. Erni Juwita Nelwan SpPD-KPTI PhD, highlighted the importance of broader protection and dengue vaccination for the age group 6 to 45 years. According to him, intervention against dengue infection must be carried out comprehensively, namely on the agent, host and environment.
“Vaccination is a very important method to help provide better protection from the serious threat of dengue fever,” he said.
“Especially for someone who has comorbidities such as diabetes mellitus, or diabetes mellitus and hypertension, if they experience dengue fever, they are at higher risk of developing severe dengue compared to those who do not have comorbidities,” Erni added.
Chair of the IDAI Immunization Task Force, Prof. Dr. Dr. Hartono Gunardi SpA(K), added that children are vulnerable to infection and supports the implementation of the 3M Plus program and other innovations.
And, President Director of PT Takeda Innovative Medicines, Andreas Gutknecht, is committed to being an active partner in education and prevention of dengue fever in Indonesia. He invited all parties to jointly commit and be active in education on dengue prevention and support innovations such as the dengue vaccine.
2024-02-03 23:00:00
#DHF #cases #increased #drastically #years #deaths #reach
